Key statistics
On Friday, MannKind Corp (NNFN:MUN) closed at 4.64, -15.01% below its 52-week high of 5.46, set on Feb 27, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 4.64 |
|---|---|
| High | 4.64 |
| Low | 4.64 |
| Bid | 4.84 |
| Offer | 4.95 |
| Previous close | 4.99 |
| Average volume | 116.60 |
|---|---|
| Shares outstanding | 307.07m |
| Free float | 301.81m |
| P/E (TTM) | 59.50 |
| Market cap | 1.69bn USD |
| EPS (TTM) | 0.0926 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 07:00 GMT.
More ▼
- MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
- MannKind Provides Business Updates and 2026 Growth Drivers
- MannKind Shares FUROSCIX® Business Updates
- MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
- MannKind to Present at the Jefferies Global Healthcare Conference
- MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
- MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
- MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
- MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
- MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
More ▼
